Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin)

Epidemiology and Health
Ji-Hyun ParkBong-Soo Cha

Abstract

Single-pill combination therapy (amlodipine/atorvastatin) might be more effective than double-pill therapy (amlodipine+atorvastatin) in patients with diabetes and concomitant hypertension requiring statin therapy. We compared the cost-effectiveness of a single-pill with that of double-pill for control of low density lipoprotein cholesterol (LDL-C) levels, with the ultimate goal of cardiovascular disease prevention, in these patients using a cost-effectiveness analysis model that considered medication adherence. Effectiveness was defined as the percentage (%) attainment of target LDL-C levels (<100 mg/dL) based on adherence for each therapy. Adherence was defined as compliance to medication (≥80% proportion of days covered). A systematic review of the literature was conducted to determine the proportion of patients who were adherent and target goal attainment based on adherence level. The annual medication costs were based on the adherence levels for each regimen. The average cost-effectiveness ratio (ACER) was calculated as the cost per % attainment of the target LDL-C level. The ACER for the single-pill regimen was lower than for the double-pill regimen (4,123 vs. 6,062 Korean won per 1% achievement of target goal). Compared w...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jun 13, 2003·Clinical Cornerstone·Alan J Garber
May 25, 2005·Archives of Internal Medicine·Richard H ChapmanJ Sanford Schwartz
Dec 7, 2005·Journal of Hypertension·Peter M NilssonSverre E Kjeldsen
Dec 21, 2005·Medical Care·Michael L JohnsonRebecca J Beyth
Jun 23, 2006·BMJ : British Medical Journal·Scot H SimpsonJeffrey A Johnson
Aug 22, 2006·Journal of Clinical Pharmacology·Menger ChungCandace Bramson
Jul 11, 2013·Statistics in Medicine·P K Andersen
Sep 4, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Giuseppe DerosaPamela Maffioli
Jan 10, 2014·Diabetes & Metabolism Journal·Eun RohUNKNOWN Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association
Mar 15, 2014·Diabetes & Metabolism Journal·Seung-Hyun KoUNKNOWN Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association
Nov 1, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Y J KimC W Lee

❮ Previous
Next ❯

Software Mentioned

CUA

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.